Galectin-9: A novel promoter of atherosclerosis progression.
Atherosclerosis
Galectin-9
Macrophages
Monocytes
Journal
Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
04
2022
revised:
09
11
2022
accepted:
16
11
2022
pubmed:
3
12
2022
medline:
15
12
2022
entrez:
2
12
2022
Statut:
ppublish
Résumé
Atherosclerosis is widely accepted to be an inflammatory disease driven by lipid accumulation and leukocyte recruitment. More recently, galectins, a family of β-galactoside binding proteins, have been shown to play a role in leukocyte recruitment among other immunomodulatory functions. Galectin (Gal) -9, a tandem repeat type galectin expressed by the endothelium in inflammatory environments, has been proposed to promote leukocyte recruitment. However, the role of Gal-9 in the context of monocyte recruitment remains elusive. Here, we characterise the immunomodulatory role of Gal-9 in context of atherosclerosis. We show that ApoE These results highlight a pathological role for Gal-9 as promoter of monocyte recruitment and atherosclerotic plaque progression, making it a novel target in the prevention of plaque formation and progression.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Atherosclerosis is widely accepted to be an inflammatory disease driven by lipid accumulation and leukocyte recruitment. More recently, galectins, a family of β-galactoside binding proteins, have been shown to play a role in leukocyte recruitment among other immunomodulatory functions. Galectin (Gal) -9, a tandem repeat type galectin expressed by the endothelium in inflammatory environments, has been proposed to promote leukocyte recruitment. However, the role of Gal-9 in the context of monocyte recruitment remains elusive.
METHODS AND RESULTS
RESULTS
Here, we characterise the immunomodulatory role of Gal-9 in context of atherosclerosis. We show that ApoE
CONCLUSIONS
CONCLUSIONS
These results highlight a pathological role for Gal-9 as promoter of monocyte recruitment and atherosclerotic plaque progression, making it a novel target in the prevention of plaque formation and progression.
Identifiants
pubmed: 36459823
pii: S0021-9150(22)01524-6
doi: 10.1016/j.atherosclerosis.2022.11.014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-68Subventions
Organisme : Medical Research Council
ID : MR/T028025/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.